In Vivo Biosafety Lab Expansion
To support the growing need of customers, we are announcing the expansion of our GMP In Vivo Biosafety IVB capabilities in North America. The 13,000 sq. ft. purpose-built space doubles the amount of laboratory and animal housing space allowing for expanded capacity for cell line characterization testing and client specific lot release programs. Additionally, this expanded footprint allows for the evaluation of adding new complementary capabilities to better support our customer’s programs.
“The expansion, scheduled to be finalized later this year, allows us to offer customers increased capacity and expansion of capabilities in support of cell line characterization studies,” said site head, Paula Niksa, Director of Operations, Biologics Testing Solutions, Massachusetts. “Charles River recognizes the increased role that biologics are playing in today’s market and we are excited to support the growth of the expansion of our In Vivo Biosafety operations.”
Learn more about our GMP in vivo capabilities offered in North America or Europe.